Gen­Sight vet Com­bal grabs $40M from No­var­tis, Roche group for sec­ond-wave gene ther­a­py biotech

Up un­til some months ago, Jean-Philippe Com­bal had been the COO at Paris-based Gen­Sight Bi­o­log­ics, fo­cused on a close­ly-watched late-stage study of an ex­per­i­men­tal gene ther­a­py for Leber’s Hered­i­tary Op­tic Neu­ropa­thy (or LHON), a rare mi­to­chon­dr­i­al dis­ease that de­stroys vi­sion. But in a quick leap, he’s now jumped ship, leav­ing CEO Bernard Gilly’s crew and launch­ing a new wave ther­a­py start­up of his own that has at­tract­ed about $40 mil­lion in start­up cash.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.